Clinical trials: Cancer, suspended
Ovarian Tumors
First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.
The study consists of two parts based on the administration of single-agent GRN-300 or in combination with paclitaxel. Part 1 (Phase IA) will test the tolerability of continuous twice a day dosing of oral GRN-300, a…
- Trial name
- NCT04711161
- Testing
- GRN-300, Paclitaxel
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Green3Bio, Inc.
Breast Cancer
Early Predictor of Herceptin Cardio Toxicity in Breast Cancer Patients
Early identification of patients at risk for cardiotoxicity represent a primary goal for cardiologist and oncologist From all adjuvant trials echocardiography is ideal for evaluating Left Ventricular function though its operator…
- Trial name
- NCT02062983
- Testing
- Herceptin
- Where
- Saudi Arabia
- Volunteers
- 50 people
- Sponsor
- National Guard Health Affairs
Colon Cancer
Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer
This is a multicenter, two-stage trial with the goal of evaluating up to 100 subjects. This trial will be performed to initiate identification of a safe and effective dose of twice-weekly, subcutaneous rNAPc2 for the second-line…
- Trial name
- NCT00443573
- Testing
- recombinant nematode anticoagulant protein c2 (rNAPc2)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- ARCA Biopharma, Inc.
Acute Myeloid Leukemia
Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia
This phase I trial tests the safety, side effects, and best dose of lintuzumab-Ac225 in combination with venetoclax and ASTX-727, and how well they work in treating patients with newly diagnosed acute myeloid leukemia (AML).
- Trial name
- NCT06802523
- Testing
- Actinium Ac 225 Lintuzumab, Biospecimen Collection, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
Background: The ability to treat early prostate cancer is still limited. Thermal ablation methods are being tested for focal prostate cancer therapy. Researchers want to improve on these methods.
- Trial name
- NCT04808427
- Testing
- TULSA-PRO
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Pain, Pancreatic Adenocarcinoma
High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain
This is an open-label, non-randomized, single-center, therapeutic trial in patients with AJCC Stage III or IV pancreatic cancer with tumor related abdominal and/or back pain to evaluate the safety of high intensity focused…
- Conditions
- Pain, Pancreatic Adenocarcinoma, Ductal Adenocarcinoma
- Trial name
- HIFU Pancreas (NCT00637364)
- Testing
- High intensity focused ultrasound, HIFU
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- CMED HIFU Development Corporation
Chemotherapeutic Agent Toxicity, Renal Toxicity
Kidney Damage in Patients Receiving Cisplatin and Ifosfamide for Solid Tumors
RATIONALE: Studying samples of blood and urine from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Conditions
- Chemotherapeutic Agent Toxicity, Renal Toxicity, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00695032
- Testing
- cisplatin, ifosfamide, laboratory biomarker analysis
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Institut Claudius Regaud
Mesothelioma
Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment
Malignant mesothelioma is a rare neoplasm that arises most commonly from the mesothelial surfaces of the pleural cavity, occasionally from the peritoneal surface, and rarely from the tunica vaginalis or pericardium.
- Trial name
- NCT01627795
- Testing
- Oshadi D and Oshadi R
- Where
- Israel
- Volunteers
- 17 people
- Sponsor
- Oshadi Drug Administration
Glioblastoma
Predicting Response Patterns to Treatment in Glioblastoma (GBM) Patients
PROPHETIC GBM - Predicting response patterns to treatment in Glioblastoma (GBM) oncology patients based on host response evaluation during anti-cancer treatments
- Trial name
- PROPHETIC (NCT04219475)
- Where
- 4 sites in Israel
- Volunteers
- 1,000 people
- Sponsor
- OncoHost Ltd.
Melanoma
The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)
Background: The gut microbiome is made up microorganisms. These include the good and bad bacteria that live in the digestive tract. Changes in the gut microbiome have been linked to the development of cancer.
- Trial name
- NCT04866810
- Testing
- Intervention Arm, Control
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia
2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML
This clinical research study is being done to answer questions about how to treat cancer. To clear cancer cells from the body, the immune system needs the action of proteins called Type 1 interferons.
- Trial name
- NCT06626633
- Testing
- CRD3874
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Maryland, Baltimore